Introduction
Colorectal cancer is a leading cause of cancer-related mortality. It arises from the accumulation of genetic mutations in normal epithelium, leading to the development of adenomas with eventual neoplastic transformation into invasive, metastatic carcinomas (1) . Despite significant progress regarding early detection and treatment of colorectal cancer, a high proportion of patients with surgically resectable tumors eventually succumb to metastatic disease originating from residual microscopic malignancy not evident at the time of surgery (1, 2) . Adjuvant therapeutic modalities such as radiotherapy and chemotherapy are designed to target residual tumor cells; however, their success is currently limited by the existence of therapy-resistant cancer cell populations (2-4). anti-IL-4 neutralizing antibody (12) or specific gene silencing of the Aurora-A kinase (13) . In Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on June 7, 2011; DOI: 10.1158/0008-5472. addition, CD133-overexpressing tumors were found to be more resistant to 5-FU-based chemotherapy and CD133 expression was associated with poor prognosis in a recent study of 501 cases of human colorectal cancer (14) . While additional studies are required to further delineate whether all heterogeneously-expressed colorectal cancer markers (6) (7) (8) (9) (10) 15 ) identify hierarchical tumor organization as posited by the cancer stem cell model (16) , and while more work is necessary to define their specific relationships, the data to date suggest preferential survival of CD133
+ colorectal cancer cells following chemotherapy, and underline the importance of identifying and ultimately targeting all possible resistance mechanisms of these aggressive tumor subpopulations (2, 3) .
We have recently cloned and characterized ABCB5 (ATP-binding cassette, sub-family B (MDR/TAP), member 5) (17) (18) (19) (20) (21) (22) , a chemoresistance gene in human melanomas (18, 23, 24) and hepatocellular carcinomas (25) preferentially expressed on CD133 + tumor cells (18, 25) , which correlates with clinical tumor progression in these malignancies according to results from several laboratories (19, (25) (26) (27) ) and serves as a major independent biomarker of tumor recurrence and poor survival in human hepatocellular carcinoma patients (25) . Our previous analysis of mRNA expression across diverse physiological and malignant human tissues demonstrated that ABCB5
is also expressed in human colorectal cancer (18) . Therefore, we hypothesized that ABCB5 might identify therapy-refractory tumor populations in patients with colorectal cancer and that ABCB5, similar to its role in melanoma (23) , might contribute to 5-FU resistance in this malignancy. Our results identify ABCB5 overexpression in clinical colorectal cancers compared to healthy controls and show that ABCB5 marks therapy-refractory tumor subpopulations following neoadjuvant 5-FU-based chemoradiation treatment in colorectal cancer patients.
Mechanistically, utilization of a colorectal cancer xenotransplantation model reveals resistance 
Materials and Methods
Clinical colorectal cancer specimens. Clinical colorectal tumor specimens were obtained from patients according to human subjects research protocols approved by institutional IRBs at the VA Boston Healthcare System and the University of Würzburg Medical School. Baseline ABCB5 expression was examined in tumors of diverse stages resected from fifteen patients not subjected to pre-operative treatment (Supplementary Table 1 ). In addition, patient-matched biopsy specimens derived from seven rectal cancer patients prior to and following neoadjuvant treatment with chemoradiation (bolus 5-FU treatment and long-course 40-52 Gy total dose radiotherapy) and subsequent curative surgical resection were included in the study (Supplementary Table 2 ), for analysis of ABCB5 expression in pre-treatment tumor biopsies and post-treatment surgically resected tumors. Immunohistochemistry was performed as described previously (19, 22 and histologically uninvolved portions of surgical specimens of the same group of colorectal cancer patients (Supplemental Table 1 ). ABCB5 staining intensity in full thickness colonic wall specimens was hereby evaluated in histologically selected areas representing only colonic epithelium in order to avoid inclusion of nonepithelial stromal, submucosa and muscular elements. In each case, ImageJ analysis software was used to quantify the pixel intensity of the selected areas as described previously (28) .
TUNEL/ABCB5 co-staining. The ApopTag TdT Enzyme Kit (Chemicon International, Billerica, MA) was used for TUNEL staining. After deparaffinisation and antigen retrieval, the colorectal cancer sections were incubated with TdT enzyme mixture which 77 ml ApopTag reaction buffer + 33 ml ApopTag TdT Enzyme (33 ml dH 2 O instead of TdT enzyme was used as a negative control) at 37°C for 1 hour and then washed with dH 2 O and PBS once for each assay.
The sections were incubated with ABCB5 mAb at 4°C overnight and then with peroxidaseconjugated sheep anti-DIG Ab (Roche, Branchburg, NJ) and AP-conjugated horse anti-mouse Ab at room temperature for 30 minutes. TUNEL staining was detected with NovaRed peroxidase substrate (Vector) and ABCB5 staining was detected with AP NBT/BCIP. Flow cytometry. Cells were harvested using Versene (Invitrogen) as described (17, 18) and dissociated HT-29 and SW480 cell cultures were passed through a 40 ȝm nylon mesh to exclude cell aggregates followed by trypan blue examination for cell viability, as described previously transfection reagent followed by puromycin selection (1μg/ml and 2μg/ml, respectively). The ABCB5 shRNA target sequence GCTGGAAAGATAGCAACTGAA was as previously MTT cell growth and cytotoxicity assays. In vitro growth kinetics of HT-29 or SW480 human colorectal cancer cells or their corresponding stable ABCB5 shRNA knockdown or vector control variants were assayed using the MTT cell proliferation assay as described previously (18) . To determine the effect of ABCB5 gene knockdown on 5-FU-induced cell killing, cells were seeded in 96-well dishes and exposed to a range of 5-FU concentrations (0.5-100nM) and the dose response of cell viability was measured after 7 days of drug treatment using a TACS MTT Cell Proliferation Assay kit (Trevigen, Gaithersburg, MD) according to the manufacturer's protocol, as previously described for doxorubicin in human melanoma cells (18) . 
Statistical Analysis. Statistical differences between expression levels of markers, between surviving cell fractions or between tumor volumes were determined using the nonparametric Mann-Whitney test, with two-sided P values of P<0.05 considered significant. Pearson correlation coefficients were calculated for assessment of ABCB5 expression-drug potency relationships. The dual criteria of P<0.05 and r>0.3 were used to identify significant negative correlations as described previously (18) .
Results

ABCB5 is expressed only on rare cells in healthy colonic mucosa but markedly increased in
human colorectal cancer. In healthy human colon, we found ABCB5 to be expressed only on rare, distinct cells residing preferentially at or near the base of colonic crypts (Fig.1A) , which also CD133-positive cells (Fig.1A) . Furthermore, ABCB5-positive crypt cells co-expressed CD133, a candidate marker of intestinal stem cells (33, 34) and this cell population represented a subset of the CD133-expressing component (Fig.1B) . Interestingly, ABCB5 and CD133 were expressed on opposite poles of individual cells, in keeping with the phenomenon of apico-basal polarity attributed to normal columnar epithelial cells (35) . In clinical human colorectal cancer specimens, ABCB5 could also be detected to co-express CD133, a marker of 5-FU-resistant tumor populations in colorectal cancer (14, 36) and a candidate marker of more aggressive colorectal cancer cells according to some reports (7, 8) , in the same tumor regions and on the same cancer cells (Fig.1C) . Intriguingly, ABCB5 was expressed at higher levels in lesser differentiated areas of human colorectal cancer specimens compared to better differentiated areas (Fig.1D, left (Fig.1D, right panel) . These results provide initial evidence that the chemoresistance mediator ABCB5 is overexpressed in human colorectal cancer. Table 2 ). Analysis of matched diagnostic rectal cancer biopsy specimens in a series of patients who underwent neoadjuvant treatment prior to curative surgical tumor resection revealed ABCB5 positivity in only 5.7±4.6% of rectal cancer cells (mean±SEM) in pre-treatment specimens ( Fig.2A, B) , whereas post-treatment specimens showed markedly increased levels of ABCB5 expression (P<0.01), with 32.3±8.8% of cancer cells staining positively for ABCB5
( Fig.2A, B) . Post-treatment rectal cancer specimens also revealed preferential co-expression of ABCB5 with CD133, in the same tumor regions and on the same cancer cells (Fig.2C ). These (Fig. 3C, D (Fig. 4A ), at both the mRNA level using RT-PCR and real-time PCR (HT-29: 64% knockdown and SW480: 65% knockdown), and at the protein level using IP-western blot analysis (Fig. 4A) (Fig. 4C ), pointing to a functional role of ABCB5 in tumorigenic growth. Next, based on identical growth characteristics of untreated control and ABCB5-KD colorectal cancer cells in vitro, we subjected ABCB5-KD or control cells to 5-FU-induced cell killing as a dose-response to increasing 5-FU concentrations in 1-week drug exposure assays, followed by cell viability measurements to assess relative cell death, using an MTT assay (18) . 
Discussion
In this study, based on our previous identification of ABCB5 mRNA expression in human colorectal cancer (18), we performed an in-depth analysis of ABCB5 expression and function involving healthy human colon specimens from nine distinct individuals, colorectal cancer specimens from twenty-three patients, and eight established colorectal cancer cell lines.
First, we found ABCB5 expression to be restricted to rare cells within the healthy human colon, but detected marked overexpression in human colorectal cancer. These results identify ABCB5 expression in clinical human colorectal cancer and parallel findings in melanoma and hepatocellular carcinoma of absent or rare ABCB5 expression in the respective non-malignant tissues, but overexpression in the corresponding malignancies (19, (25) (26) (27) . Intriguingly, we found ABCB5 to be co-expressed with CD133 on the same individual cells in healthy colon and in human colorectal cancer, also resembling previous findings of co-expression of these molecular markers in human skin and malignant melanoma (17) (18) (19) and hepatocellular carcinoma (25) . Since CD133 represents a candidate intestinal stem cell marker (34) and potential marker of colorectal cancer stem cells (7, 8) , and because colorectal cancers can originate from physiological intestinal stem cells (34, 38) 
